Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

In the UK, anxiety, panic attacks and insomnia are not listed as possible side-effects for Ozempic, Wegovy or Mounjaro.

UNIONDALE, NY / ACCESS Newswire / June 9, 2025 / Marquis Who's Who honors Mike Martin as a respected leader in the ...

A new analysis shows no clear link between paternal valproate use and harm in offspring, raising questions about the EMA ...

BioBridges adds job growth to the Raleigh-Durham area BioBridges, a leading provider of life sciences solutions, has brought more than 20 n ...

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

In this edition of Open Interest, we look at how the focus on GLP-1 could reduce household dietary intake and grocery bills.

WEIGHT loss jabs could prevent a medication taken by millions of women from working – and increase patients’ risk of cancer. The British Menopause Society said the jabs could cause ...

Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...